← Avidity Biosciences, Inc. (RNAM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Avidity Biosciences, Inc. (RNAM)
Biotechnology · market cap $11.2B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Avidity Biosciences (RNAM) is a clinical-stage biotechnology company with 511 employees and a market capitalization of approximately $11.25 billion. Its pipeline is built around AOC (Antibody Oligonucleotide Conjugate) technology, with three Phase 2 assets targeting Duchenne Muscular Dystrophy (AOC 1044), Myotonic Dystrophy Type 1 (AOC 1001), and Facioscapulohumeral Muscular Dystrophy (AOC 1020). Key financial details including cash position, runway, and dilution metrics are not available in the provided data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AOC 1044 | Phase 3 | DMD |
| AOC 1001 | Phase 2 | DM1 |
| AOC 1020 | Phase 2 | FSHD |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RNAM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.